Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 placebo-controlled study of seladelpar in primary biliary cholangitis
NL-OMON48405Phase 3Recruiting
- Sponsor
- CymaBay Therapeutics
- Start
- Sep 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised trial of seladelpar in primary biliary cholangitis (PBC), sponsored by CymaBay Therapeutics. Started Sep 2019; status: recruiting.
02
Drugs
seladelpar
03
Conditions
primary biliary cholangitis (PBC)
Beyond the preview
Go deeper on NL-OMON48405.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON48405.